​

Elutia (ELUT) Revenue & Revenue Breakdown

OverviewForecastFinancialsChartTranscripts

Elutia Revenue Highlights

Latest Revenue (Y)

$12.29M

Latest Revenue (Q)

$3.32M

Main Segment (Y)

Women's Health

Elutia Revenue by Period

Elutia Revenue by Year

DateRevenueChange
2025-12-31$12.29M-49.57%
2024-12-31$24.38M-1.50%
2023-12-31$24.75M3.76%
2022-12-31$23.85M-49.68%
2021-12-31$47.39M11.03%
2020-12-31$42.68M-0.51%
2019-12-31$42.90M9.90%
2018-12-31$39.04M-

Elutia generated $12.29M in revenue during NA 2025, up -49.57% compared to the previous quarter, and up 28.80% compared to the same period a year ago.

Elutia Revenue by Quarter

DateRevenueChange
2025-09-30$3.32M-46.94%
2025-06-30$6.26M3.86%
2025-03-31$6.03M10.28%
2024-12-31$5.47M-7.67%
2024-09-30$5.92M-5.87%
2024-06-30$6.29M-6.02%
2024-03-31$6.69M13.94%
2023-12-31$5.88M-4.11%
2023-09-30$6.13M-3.53%
2023-06-30$6.35M-0.64%
2023-03-31$6.39M-49.53%
2022-12-31$12.66M116.53%
2022-09-30$5.85M-53.72%
2022-06-30$12.64M9.94%
2022-03-31$11.49M5.84%
2021-12-31$10.86M-5.43%
2021-09-30$11.48M-

Elutia generated $3.32M in revenue during Q3 2025, up -46.94% compared to the previous quarter, and up 52.82% compared to the same period a year ago.

Elutia Revenue Breakdown

Elutia Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24
Cardiovascular$3.15M$2.92M
Women's Health$9.14M$11.55M

Elutia's latest annual revenue breakdown by segment (product or service), as of Dec 25: Women's Health (74.33%), and Cardiovascular (25.67%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Women's Health$2.12M$2.38M$2.01M$2.63M$5.88M$3.10M$2.57M
Cardiovascular$1.15M$944.00K$736.00K$326.00K$1.27M$562.00K$1.08M

Elutia's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Women's Health (64.88%), and Cardiovascular (35.12%).

Elutia Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
CELUCelularity$22.77M$5.28M
ELUTElutia$12.29M$3.32M
RNXTRenovoRx$43.00K$266.00K
LTRNLantern Pharma--
RVPHReviva Pharmaceuticals--
BCABBioAtla--
CALCCalciMedica--
TVRDTvardi Therapeutics--
PYPDPolyPid--
ANVSAnnovis Bio--

ELUT Revenue FAQ

What is Elutia’s yearly revenue?

Elutia's yearly revenue for 2025 was $12.29M, representing a decrease of -49.57% compared to 2024. The company's yearly revenue for 2024 was $24.38M, representing a decrease of -1.50% compared to 2023. ELUT's yearly revenue for 2023 was $24.74M, representing an increase of 3.76% compared to 2022.

What is Elutia’s quarterly revenue?

Elutia's quarterly revenue for Q3 2025 was $3.32M, a -46.94% decrease from the previous quarter (Q2 2025), and a -43.89% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $6.26M, a 3.86% increase from the previous quarter (Q1 2025), and a -0.45% decrease year-over-year (Q2 2024). ELUT's quarterly revenue for Q1 2025 was $6.03M, a 10.28% increase from the previous quarter (Q4 2024), and a -9.92% decrease year-over-year (Q1 2024).

What is Elutia’s revenue growth rate?

Elutia's revenue growth rate for the last 3 years (2023-2025) was -50.32%, and for the last 5 years (2021-2025) was -74.06%.

What are Elutia’s revenue streams?

Elutia's revenue streams in c 25 are Cardiovascular, and Women's Health. Cardiovascular generated $3.16M in revenue, accounting 25.67% of the company's total revenue, up 8.23% year-over-year. Women's Health generated $9.14M in revenue, accounting 74.33% of the company's total revenue, down -20.90% year-over-year.

What is Elutia’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Elutia was Women's Health. This segment made a revenue of $9.14M, representing 74.33% of the company's total revenue.